Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension (RVMET)

This study is ongoing, but not recruiting participants.
Heart and Stroke Foundation of Ontario
Information provided by (Responsible Party):
Lisa Mielniczuk, Ottawa Heart Institute Research Corporation Identifier:
First received: March 29, 2012
Last updated: January 31, 2017
Last verified: January 2017
The purpose of this study is to evaluate patterns of metabolic activity in the heart of patients with pulmonary arterial hypertension(PAH). Patients with PAH are at risk of developing weakness or failure of the right side of the heart.It is possible that there is a relationship between the development of heart failure and the way the heart uses energy sources, such as sugar. This study is designed to evaluate the way the heart uses sugar uptake in patients with PAH using positron emission tomography(PET imaging)

Condition Intervention
Pulmonary Arterial Hypertension
Radiation: FTHA, FDG PET imaging.

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Basic Science
Official Title: Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension

Resource links provided by NLM:

Further study details as provided by Ottawa Heart Institute Research Corporation:

Primary Outcome Measures:
  • Cardiopulmonary death OR clinical right heart failure hospitalization [ Time Frame: 1year ]
    Clinical RHF admission requiring ONE of the following:intravenous diuretics or an increase in oral diuretics >50%of baseline for at least 7 days.

Secondary Outcome Measures:
  • Change in right ventricular size and function as measured by cardiac MRI, between baseline and 1 year. [ Time Frame: 1 year ]

Enrollment: 20
Study Start Date: January 2011
Estimated Study Completion Date: December 2017
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FTHA/GDF PET imaging

This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.

Both groups will undergo FTHA/FDG PET imaging.

Radiation: FTHA, FDG PET imaging.
Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).

Detailed Description:

PAH results in premature death as a result of right ventricular dysfunction. However, there are substantial differences among patients in their tendency to develop right heart failure. This study proposes to determine if right ventricular (RV) changes can predict the development of right heart failure in patients with PAH.

In addition, the study aims to evaluate the relationship of right ventricular metabolism to other physiologic responses in PAH,including:pulmonary vascular resistance, serum BNP and changes in cardiac hypertrophy and function. In conjunction with hemodynamic measurements, biomarkers and cardiac magnetic resonance imaging (MRI); RV metabolism will be evaluated with (18F) FTHA and (18F)FDG cardiac PET imaging.

A cohort of 20 age sex matched individuals will serve as normal controls. These subjects will have no known cardiac or pulmonary disease with normal ventricular function and estimates pulmonary pressures on echocardiogram.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:(PATIENTS)

  • Patients with diagnosis of Category 1 pulmonary arterial hypertension due to any of the following: idiopathic, familial, associated with connective tissue disease, HIV disease or anorexigen use.
  • All patients who will require a right heart catheterization for further clinical management and/or diagnosis.
  • Patients will be considered eligible if they have no significant coronary artery disease (stenosis > 70% in a proximal or mid major coronary artery) or moderate coronary artery disease (60-70%) with abnormal left ventricular function (EF<50%)
  • Patients will be considered eligible in the absence of current or recent evidence of right heart failure.
  • No previous hospital admission or requirements of intravenous diuretics for right heart failure within 6 months of enrolment.
  • No increase in oral diuretics to control fluid volume within 6 months prior to enrolment
  • No current symptoms and signs of fluid retention or right heart strain, including any of the following: development of new ascites or peripheral edema > = 2+, JVP >7 cm above the sternal angle or a right atrial pressure >14 mmHg at the time of right heart catheterization.
  • In addition, we will include a small cohort of up to 15 patients with PAH and current RHF.

Exclusion Criteria:

  • Patients with known significant coronary artery disease(defined as known stenosis >70% in a proximal or mid major artery or moderate coronary artery disease (60-70%)in a coronary artery and associated left ventricular ejection fraction <50%.
  • Patients with diabetes mellitus who require the use of oral hypoglycemics and or insulin.
  • Implantable metal devices, incompatible with magnetic resonance imaging.
  • Other contraindications of magnetic resonance imaging.

Normal Control Subjects:

  • Subjects will have no known cardiac or pulmonary disease.
  • Normal ventricular function and estimated pulmonary pressures on echocardiogram.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01572077

Canada, Ontario
University of OttawaHeart Institute
Ottawa, Ontario, Canada, K1Y4W7
Sponsors and Collaborators
Ottawa Heart Institute Research Corporation
Heart and Stroke Foundation of Ontario
Principal Investigator: Lisa M Mielniczuk, MD University of Ottawa Heart Institiute
  More Information

Responsible Party: Lisa Mielniczuk, Co- Medical Director Pulmonary Hypertension Clinic, Ottawa Heart Institute Research Corporation Identifier: NCT01572077     History of Changes
Other Study ID Numbers: 2010539-01H
Study First Received: March 29, 2012
Last Updated: January 31, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Heart Failure
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases processed this record on May 25, 2017